- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals secures exclusive rights to a 40-product hospital portfolio in Iraq | 240 | GlobeNewswire (Europe) | Newbury Pharmaceuticals AB has, through its subsidiary Newbury Pharmaceuticals S.A, signed an exclusivity agreement with an established Chinese pharmaceutical manufacturer granting Newbury exclusive... ► Artikel lesen | |
| 17.08. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals accelerates its neuroscience ambitions with a new partnership for Guanfacine tablets | 222 | GlobeNewswire (Europe) | Newbury has signed a new licence and supply agreement with one of its existing partners to register and launch Guanfacine in Sweden. Guanfacine, 1, 2, 3 and 4 mg prolonged release tablets, is a selective... ► Artikel lesen | |
| 13.07. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Tofacitinib Newbury | 365 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Tofacitinib Newbury 5 mg and 10 mg film-coated tablets in Sweden as the first country in a Scandinavian... ► Artikel lesen | |
| NEWBURY PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.07. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Dalbavancin Newbury | 1.514 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Dalbavancin Newbury 500 mg powder for concentrate for solution for infusion in Sweden. No further country... ► Artikel lesen | |
| 08.07. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - May 2026 | 209 | GlobeNewswire (Europe) | Quarter 3, March 2026 - May 2026Net revenue was 8 933 (6 686) tkr.EBITDA was -3 964 (-5 691) tkr.Operating cash flow was -10 286 (-5 787) tkr.Interim period, September 2025 - May 2026Net revenue was... ► Artikel lesen | |
| 15.04. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - February 2026 | 206 | GlobeNewswire (Europe) | Quarter 2, December 2025 - February 2026Net revenue was 8 454 (12 434) tkr.EBITDA was -4 144 (-973) tkr.Operating cash flow was 2 260 (-6 371) tkr.Interim period, September 2025 - February 2026Net revenue... ► Artikel lesen | |
| 26.03. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals extends and increases loan agreement to SEK 30m, convenes EGM | 227 | GlobeNewswire (Europe) | Newbury Pharmaceuticals AB has agreed to extend and increase the existing loan agreement with AB Slädens Pensionsstiftelse nr 3, securing SEK 30 million in total financing through to 30 June 2027, and... ► Artikel lesen | |
| 18.03. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals has entered into a new partnership for Prucalopride tablets | 273 | GlobeNewswire (Europe) | Newbury has signed a contract with a new partner to register and launch Prucalopride in Sweden. Prucalopride, 1 and 2 mg tablets, is a selective, high affinity 5-HT4 receptor agonist which targets the... ► Artikel lesen | |
| 29.01. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures 12-Month Pazopanib Tender in Denmark | 240 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce that it has been awarded a 12-month tender for Pazopanib Newbury with the Danish procurement body Amgros, commencing on June 1, 2026.
Pazopanib Newbury... ► Artikel lesen | |
| 21.01. | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals interim report September 2025 - November 2025 | 233 | GlobeNewswire (Europe) | Quarter 1, September 2025 - November 2025Net revenue was 11 720 (6 538) tkr.EBITDA was -5 524 (-3 759) tkr.Operating cash flow was -6 549 (4 792) tkr.Cash position in the end of period was 7 919 (19... ► Artikel lesen | |
| 11.11.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO | 315 | GlobeNewswire (Europe) | The company today announced that Karl Karlsson, currently Executive Chairman of the Board, has been appointed CEO of Newbury Pharmaceuticals AB.
Lars Minor is simultaneously stepping down from his role... ► Artikel lesen | |
| 29.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals year-end report September 2024 - August 2025 | 289 | GlobeNewswire (Europe) | Quarter 4, June 2025 - August 2025Net revenue was 5 915 (21 123) tkr.EBITDA was -5 876 (2 402) tkr.Operating cash flow was -5 004 (130) tkr.Year-end period, September 2024 - August 2025Net revenue was... ► Artikel lesen | |
| 24.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury | 270 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in Sweden.
Mirtazapin Newbury is a noradrenergic and specific... ► Artikel lesen | |
| 23.10.25 | Newbury Pharmaceuticals AB: Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury | 271 | GlobeNewswire (Europe) | Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Ivermectin Newbury 10 mg/g cream in Denmark as the first country in a Scandinavian registration procedure.... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES | 40,180 | -0,04 % | Teva/Sanofi: Duvakitug Maintains Meaningful Efficacy Improvements In Long-term Extension Study | PETAH TIKVA (dpa-AFX) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension... ► Artikel lesen | |
| MERCK KGAA | 144,10 | -1,54 % | Eli Lillys Umsatzsprung, Mercks 11,3-Milliarden-Dollar-Deal: Wie Zelltherapien in die Wachstumsstory der Pharmabranche passen | ||
| BAYER | 43,940 | -0,61 % | Bayer: Wird Nubeqa zum größten Medikament der Firmengeschichte? | Auf dem Krebskongress ESMO stehen Zwischendaten zu Bayers Prostatakrebsmittel Nubeqa an. Die BofA rechnet mit einem klaren Erfolg und traut dem Medikament den Rekord in der Konzerngeschichte zu. Bayer... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 50,13 | +0,22 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| IAMBIC THERAPEUTICS | 14,520 | -1,02 % | Biotech an der Börse: Iambic-IPO bringt 150 Millionen USD für Krebsmedikamente | Das US-Biotechunternehmen Iambic setzt bei neuen Krebsmedikamenten auf künstliche Intelligenz. Mit dem frischen Börsenkapital will es klinische Studien voranbringen und seine Forschungstechnik ausbauen.... ► Artikel lesen | |
| NOVO NORDISK | 35,375 | +0,65 % | Novo Nordisk muss zittern: Eli Lilly vor Milliardenchance: Neue Abnehmpille nimmt wichtige EU-Hürde! | Eli Lillys Abnehmpille Foundayo nimmt eine wichtige EU-Hürde. Die mögliche Zulassung verschärft den Milliardenwettbewerb mit Novo Nordisk Enthaltene Werte: US5324571083,DK0062498333Den vollständigen... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,130 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Aquestive nach FDA-Fortschritten | ||
| GENERATE BIOMEDICINES | 12,800 | +0,08 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,460 | +0,10 % | Stifel reiterates Buy rating on LB Pharmaceuticals stock at $53 | ||
| KARDIGAN | 12,740 | 0,00 % | Baird stuft Kardigan mit "Outperform" ein - Kursziel 43 US-Dollar | ||
| OMNIAB | 4,770 | -0,21 % | OmniAb auf der LD Micro Konferenz: Lizenzgebühren, Skalierung und Geduld im Fokus | ||
| BRIGHT MINDS BIOSCIENCES | 52,50 | -0,36 % | Levoit and Cosori: 5 Back to School Wellness Heroes for the Bright Minds of Tomorrow | DUBAI, UAE, Aug. 21, 2026 /PRNewswire/ -- Levoit and Cosori unveil five smart home solutions to tackle back to school stresses: polluted indoor air, relentless AC dryness, post snack floor... ► Artikel lesen | |
| APNIMED | 18,540 | +0,05 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| ROCHE | 423,00 | -0,57 % | RBC stuft ROCHE HOLDINGS AG auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Roche mit einem Kursziel von 400 Franken auf "Outperform" belassen. Seine Umsatzprognose für das dritte Jahresviertel liege... ► Artikel lesen | |
| SANOFI | 74,15 | -0,66 % | RBC stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Sanofi vor Zahlen für das dritte Quartal von 80 auf 75 Euro gesenkt und die Einstufung auf "Sector Perform" belassen. Die Stärke... ► Artikel lesen |
NEWBURY PHARMACEUTICALS AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,055 (+59,78 %) liegt der Kurs bei 0,147 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWBURY PHARMACEUTICALS AB finden Sie auf Wallstreet Online.